23:48 , Jun 28, 2019 |  BC Extra  |  Company News

June 28 Company Quick Takes: FDA approves Pfizer's biosimilar of Avastin; plus Aimmune, PeptiDream, Novartis and Just/Teva

Pfizer gets second FDA-approved biosimilar with Zirabev approval  FDA approved Zirabev bevacizumab-bvzr from Pfizer Inc. (NYSE:PFE) to treat metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell long cancer; recurrent glioblastoma; metastatic...
19:53 , May 13, 2019 |  BC Extra  |  Company News

May 13 Company Quick Takes: PeptiDream/JCR, Grail, Lilly, Onconova/HanX, Regeneron

PeptiDream, JCR deal produces drug carriers for CNS delivery  The 2016 partnership between PeptiDream Inc. (Tokyo:4587) and JCR Pharmaceuticals Co. Ltd. (Tokyo:4552) has led to the development of constrained peptides that bind TFRC and are...
17:09 , Jan 25, 2019 |  BC Week In Review  |  Company News

Shionogi, PeptiDream to develop BBB peptides

Shionogi & Co. Ltd. (Tokyo:4507) and PeptiDream Inc. (Tokyo:4587) partnered to use PeptiDream's Peptide Discovery Platform System to identify macrocyclic peptide candidates against multiple blood-brain barrier targets from Shionogi. PeptiDream will receive an undisclosed upfront...
21:05 , Jan 10, 2019 |  BC Innovations  |  Emerging Company Profile

Kleo: small molecule immuno-oncology

Kleo Pharmaceuticals Inc. is tapping small molecules' advantages over biologics by synthesizing compounds that mimic or modify the functions of antibodies as cancer immunotherapies. The company spun out of Yale University in 2015 with IP...
15:56 , Nov 16, 2018 |  BC Week In Review  |  Financial News

Kleo raises $21M series B to advance to clinic in 2020

Immuno-oncology company Kleo Pharmaceuticals Inc. (New Haven, Conn.) raised $21 million in an untranched series B round on Nov. 13 to propel its next-generation Antibody Recruiting Molecules (ARMs) into the clinic by 2020. The round...
23:28 , Feb 26, 2018 |  BC Extra  |  Company News

Management tracks: Vertex, Basilea

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said CMO and EVP of Global Medicines Development and Medical Affairs Jeffrey Chodakewitz will retire, effective April 1. He is succeeded by Vertex SVP of Clinical Development and Medical Affairs Reshma...
20:18 , Jan 12, 2018 |  BC Extra  |  Company News

Management tracks: Ipsen, PeptiDream

Ipsen Group (Euronext:IPN; Pink:IPSEY) said President of Ipsen North America Cynthia Schwalm is stepping down. She is succeeded by Richard Paulson as EVP and CEO, effective Feb 5. He was VP and general manager of...
23:34 , Nov 30, 2017 |  BC Extra  |  Company News

Bayer reorganizes R&D

Bayer AG (Xetra:BAYN) said Thursday it will consolidate its R&D into one unit led by Jörg Möller. Möller, the head of development of the company’s pharmaceutical division, will become head of R&D, effective Jan. 1....
20:03 , Nov 17, 2017 |  BC Week In Review  |  Company News

PeptiDream identifying peptide candidates against Bayer targets

Bayer AG (Xetra:BAYN) and PeptiDream Inc. (Tokyo:4587) partnered to use PeptiDream's Peptide Discovery Platform System to identify macrocyclic peptide candidates against cancer and cardiovascular disease targets from Bayer. The pharma will also have an option...
00:09 , Nov 17, 2017 |  BC Extra  |  Company News

FDA committee votes no on Bayer's inhaled Cipro

FDA’s Antimicrobial Drugs Advisory Committee voted against approval of Cipro ciprofloxacin inhalation powder from Bayer AG (Xetra:BAYN) to reduce exacerbations in adults with non-cystic fibrosis bronchiectasis and bacterial respiratory pathogens. The committee voted 9-6 and...